IMU Biosciences Raises £11.5M to Advance CytAtlas® Platform
IMU Biosciences, a London, UK-based techbio company, has recently secured £11.5M in Series A funding. The funding round was led by Molten Ventures and will be used to advance the company's roadmap, particularly its novel CytAtlas® platform. The funds will also support the establishment of new strategic partnerships and projects, as well as the expansion of its operations into the Boston/Cambridge, MA, area. Dr Adam Laing, the founder of IMU Biosciences, is spearheading the company's efforts in combining deep, systems-level immune profiling with a proprietary AI platform to create a comprehensive immune atlas that encompasses human health and disease.
The CytAtlas® platform developed by IMU Biosciences focuses on harnessing the power of the immune system to revolutionize research and clinical practice.
By applying this platform, the company aims to transform various fields, including diagnostics, drug development, and treatment response. This technology holds significant potential in areas such as immune-oncology, cell therapy, autoimmune disorders, and transplantation. With the funding secured from the Series A round, IMU Biosciences is confident in its ability to drive innovation and improve precision medicine by offering more effective therapies and reducing failure rates in clinical trials.
As part of the recent fundraising activities, IMU Biosciences made key appointments to its board of directors. Tim Haines assumed the position of Non-executive Chair, while Dr Oliver Nussbaumer, Ph.D., and Inga Deakin, D.Phil., were appointed as Non-executive Directors. These additions to the leadership team further strengthen IMU Biosciences' expertise and strategic capabilities, enabling the company to execute its growth plans and enhance its impact in the field of techbio.
They've invested in IMU Biosciences
Get to know these Healthtech investors
Click here for a full list of 6,481+ startup investors in the UK